| Factor Information | |
|---|---|
| Data ID | 520 |
| Factor | percent predicted peak expiratory flow rate(PEFR) |
| Description | Predicted peak expiratory flow rate in CHD-APAH was lower than that in CHD without APAH. |
| Biomarker | NA |
| Classification | E11 (physiological factor - physical sign) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | medical research council dyspnea score (Inverse correlations) |
| p Value | 0.0014 |
| Conclusion | Raised biomarkers for inflammation were found in CHD-APAH. Significant abnormalities in airway physiology may contribute to the dyspnea but are not driven by inflammation as assessed by circulating and sputum cytokines. A relationship between increased serum endothelin-1 and airway dysfunction may relate to its bronchoconstrictive properties. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 466 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/TGA/DILV/TA/TOF/PS/TA/EA |
| Reference | |
|---|---|
| PMID | 29444773 |
| Year | 2018 |
| Title | Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | blood and induced sputum | |
| Region | Bristol, United Kingdom | |
| Method | Spirometry, gas transfer, whole body plethysmography and lung clearance index | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | Surgical Operation | |
| Group | CHD-PAH(Treatment) | CHD without PAH(Control) |
| Number | 20 | 20 |
| Age | Median age (IQR): 42.7 (33.1–57.7) years | N/A |
| Gender (Male: Female) | 8:12 | N/A |
| Marker Level | 83.7 (65.9–99.9) | 111.0 (88.8–119.6) |
